tradingkey.logo
tradingkey.logo
Search

Pharmala Biotech Executes Definitive Agreement To Form Special Purpose Vehicle, Restora Neurosciences, For Clinical Development Of Patented Novel Mdxx Molecule Apa-01

ReutersMay 13, 2026 12:37 PM
facebooktwitterlinkedin
View all comments0

- Pharmala Biotech Holdings Inc MDMA.CD:

  • PHARMALA BIOTECH EXECUTES DEFINITIVE AGREEMENT TO FORM SPECIAL PURPOSE VEHICLE, RESTORA NEUROSCIENCES, FOR CLINICAL DEVELOPMENT OF PATENTED NOVEL MDXX MOLECULE APA-01

  • PHARMALA BIOTECH HOLDINGS INC - CO AND ALUVARIS TO EACH HOLD 50% OF RESTORA NEUROSCIENCES SPV

  • PHARMALA BIOTECH HOLDINGS INC - RESTORA TO PAY PHARMALA $500,000 ONE-TIME LICENSE FEE UPON FUNDING THRESHOLD

  • PHARMALA BIOTECH HOLDINGS INC - LICENSE BECOMES FINAL WHEN RESTORA RAISES AT LEAST $2.5 MILLION IN CASH SUBSCRIPTIONS

  • PHARMALA BIOTECH HOLDINGS INC - TO GRANT RESTORA EXCLUSIVE WORLDWIDE ROYALTY-BEARING LICENSE FOR APA-01

  • PHARMALA BIOTECH HOLDINGS INC - TO RECEIVE 3% PERPETUAL ROYALTY ON NET SALES OF LICENSED PRODUCTS

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.

Comments (0)

Click the $ button, enter the symbol, and select to link a stock, ETF, or other ticker.

0/500
Commenting Guidelines
Loading...

Recommended Articles

Tradingkey
KeyAI